1. |
|
|
2. |
|
|
3. |
- Lerner, Ulf H, et al.
(författare)
-
Cysteine proteinases in osteoclast function and recruitment
- 2004
-
Ingår i: Biological Mechanisms of Tooth Movement and Craniofacial Adaptation. - Boston, Massachusetts, USA : Harvard Society for the Advancement of Orthodontics. - 0963204750 ; , s. 227-227
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
4. |
- Bradley, Jean-Claude, et al.
(författare)
-
Beautifying Data in the Real World
- 2009. - 1
-
Ingår i: Beautiful Data. - Sebastol, USA : O'Reilly. - 9780596157111 ; , s. 259-278
-
Bokkapitel (populärvet., debatt m.m.)
|
|
5. |
- Ur-Rehman, Tofeeq, 1971-, et al.
(författare)
-
Preliminary pharmacokinetics of the bacterial virulence inhibitor N'-(3,5-dibromo-2-hydroxy-benzylidenene)-nicotinic acid hydrazide
- 2012
-
Ingår i: Advances in Yersinia Research. - New York, NY : Springer. - 9781461435600 - 9781461435617 ; , s. 349-356
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Bacterial virulence inhibitors are potential novel drugs that may be used to treat infections. N′-(3,5-dibromo-2-hydroxy-benzylidene)-nicotinic acid hydrazide, ME0052, has been shown to inhibit type III secretion (T3S) and virulence in several Gram-negative enteric pathogens including Yersinia pseudotuberculosis. In vitro data suggest that ME0052 may be developed into drugs against bacterial gastroenteritis. Here we describe preliminary pharmacokinetics of ME0052 after intraperitoneal and subcutaneous administration in mice. The aim of this work was to identify suitable formulations and to determine pharmacokinetic parameters prior to testing in animal infection models. Peak plasma concentrations above the IC50 for virulence inhibition were achieved with high dose formulations and the elimination half-life was prolonged from 0.5 to 3.4 h using a poloxamer 407-based slow-release formulation.
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
- Lavant, Ewa H., et al.
(författare)
-
HLA DR-DQ genotyping by capillary electrophoresis for risk assessment for celiac disease.
- 2013
-
Ingår i: Clinical Applications of Capillary Electrophoresis. - Totowa, NJ : Humana Press. - 9781627030281 - 9781627030298 ; 919, s. 297-307
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- The risk for celiac disease (CD) is clearly related to specific HLA DQA1 and DQB1 alleles, but HLA -typing is often considered too costly for frequent use.Here we present a method using sequence-specific primed PCR (PCR-SSP) for HLA-DR-DQ genotyping optimized for capillary electrophoresis on Applied Biosystems 3130xl Genetic Analyzer. Requiring a total of three PCR reactions and a single electrophoretic step, this method reduces the reagent expenses and technical time for directed HLA typing to distinguish risk alleles for CD, with a sufficient throughput for large-scale screening projects.
|
|